FibroBiologics adds sports agent Leigh Steinberg to board of directors

FibroBiologics, Inc. (Nasdaq: FBLG) said its Board of Directors appointed Leigh Steinberg as a Class II director effective August 20, 2026, with a term running until the 2028 annual meeting of stockholders, according to an 8-K filed August 24, 2026.

Steinberg will receive compensation in line with the company's other non-employee directors under its existing director pay policy, which may be amended over time.¹ The filing states he is not party to any transaction with the company requiring disclosure under Item 404(a) of Regulation S-K, and there are no arrangements tied to his selection as a director.¹ The company also signed its standard indemnification agreement with him, covering certain liabilities tied to his service as a director.¹

FibroBiologics describes itself as a clinical-stage biotechnology company with 270+ patents issued and pending, focused on developing therapeutics using fibroblasts and fibroblast-derived materials.¹

Steinberg is Chief Executive Officer of Steinberg Sports & Entertainment¹ and has spent decades representing professional athletes, negotiating what the company said totals over $4 billion in contracts, and directing more than $800 million to charitable causes, per the release. Starting in 1994, he began convening what the company calls annual "brain health summits" pairing neurologists with athletes on traumatic brain injury issues. He has since started a foundation, described by the company as focused on neurological injury research, awareness, and treatment.

CEO Pete O'Heeron said Steinberg will be a powerful voice at the board table as the company advances its fibroblast-based pipeline, including its human longevity program.¹ Steinberg said he intends to put his experience, relationships, and negotiating background to work for the company and its patients.¹